中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
首页 机构 成果 学者
  
  1. CAS IR Grid
  2. 上海药物研究所
  3. 中国科学院上海药物研究所
  4. 国家级研究中心
  5. 原创新药研究全国重点实验室
Phospholipid complex-based microemulsion for treating concurrence of primary sclerosing cholangitis and inflammatory bowel disease via gut-liver crosstalk

文献类型：期刊论文

作者He, Yihao1,2; Guo, Ru1,2; Yang, Lu4; Li, Ling1; Zhang, Tong1; Wang, Bing2; Huang, Yongzhuo2,3,4,5
刊名CHINESE CHEMICAL LETTERS
出版日期2025-10-01
卷号36期号:10页码:6
关键词Paeoniflorin Phospholipid complex-based microemulsion Primary sclerosing cholangitis Inflammatory bowel disease Macrophage regulation
ISSN号1001-8417
DOI10.1016/j.cclet.2024.110778
英文摘要The concurrence of primary sclerosing cholangitis (PSC) and inflammatory bowel disease (IBD) presents a therapeutic challenge, often necessitating liver transplantation in severe cases. Paeoniflorin (PAE), known for its immunomodulatory and anti-inflammatory properties but with very high-water solubility and low permeability, is formulated into a paeoniflorin/phospholipid complex microemulsion (PAE-ME) to enhance its delivery in this study. It demonstrated the PAE-ME's macrophage-regulating ability to repolarize the pro-inflammatory M1 subtype to the anti-inflammatory M2 type and reduce inflammatory cytokine release. In a PSC-IBD mouse model, PAE-ME alleviated the symptoms and regulated bile acid balance. Given the close connection and crosstalk between the liver and intestine, PAE-ME yielded a synergistic therapeutic effect on both the liver and intestinal lesions. These findings suggest a promising translational approach for complex comorbidities by acting on the liver-gut axis. (c) 2025 Published by Elsevier B.V. on behalf of Chinese Chemical Society and Institute of Materia Medica, Chinese Academy of Medical Sciences.
WOS关键词MACROPHAGES ; ETIOPATHOGENESIS ; PAEONIFLORIN ; CHOLESTASIS
资助项目Key Research and Development Program of China , China[2022YFE0203600] ; National Natural Science Foundation of China[82341232] ; National Natural Science Foundation of China[81925035] ; Department of Science and Technology of Guangdong Province[2021B0909050003] ; Chinese Academy of Sciences President's International Fellowship Initiative[2024VBB0004] ; Scientific Innovation Group Project in Zhongshan[CXTD2022011] ; Program of Shanghai Committee of Science and Technology , China[22S21902900]
WOS研究方向Chemistry
语种英语
WOS记录号WOS:001540575300013
出版者ELSEVIER SCIENCE INC
源URL[http://119.78.100.183/handle/2S10ELR8/321186]  
专题国家级研究中心_原创新药研究全国重点实验室
通讯作者Zhang, Tong; Wang, Bing; Huang, Yongzhuo
作者单位1.Shanghai Univ Tradit Chinese Med, Sch Pharm, Shanghai 201203, Peoples R China
2.Chinese Acad Sci, Shanghai Inst Materia Med, State Key Lab Drug Res, Shanghai 201203, Peoples R China
3.Chinese Acad Sci, Zhongshan Inst Drug Discovery, Shanghai Inst Materia Med, Zhongshan 528437, Peoples R China
4.Nanjing Univ Chinese Med, Sch Chinese Materia Med, Nanjing 210023, Peoples R China
5.NMPA Key Lab Qual Res & Evaluat Pharmaceut Excipie, Shanghai 201203, Peoples R China
推荐引用方式
GB/T 7714		 He, Yihao,Guo, Ru,Yang, Lu,et al. Phospholipid complex-based microemulsion for treating concurrence of primary sclerosing cholangitis and inflammatory bowel disease via gut-liver crosstalk[J]. CHINESE CHEMICAL LETTERS,2025,36(10):6.
APA He, Yihao.,Guo, Ru.,Yang, Lu.,Li, Ling.,Zhang, Tong.,...&Huang, Yongzhuo.(2025).Phospholipid complex-based microemulsion for treating concurrence of primary sclerosing cholangitis and inflammatory bowel disease via gut-liver crosstalk.CHINESE CHEMICAL LETTERS,36(10),6.
MLA He, Yihao,et al."Phospholipid complex-based microemulsion for treating concurrence of primary sclerosing cholangitis and inflammatory bowel disease via gut-liver crosstalk".CHINESE CHEMICAL LETTERS 36.10(2025):6.

入库方式： OAI收割

来源：上海药物研究所

浏览0
下载0
收藏0
其他版本

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。